Recruitment strategies for a possible tamoxifen trial.
Participants in a primary prevention trial using tamoxifen to prevent breast cancer should comprise a sample of (a) age-eligible women from the "general population," (b) higher risk sisters of breast cancer patients, (c) women participating in mammography screening programs, or (d) patients of (or other users of) primary care physicians' offices. The recruitment should consider the risk of breast cancer among eligible women, likelihood of adherence to protocol, and unbiased and accurate measurement of endpoints. The Risks for coronary heart disease, hypertension, diabetes, osteoporosis, and other cancers, especially uterine cancer, must also be evaluated. Recruitment is feasible and should not be the limiting factor in the decision to undertake a primary prevention trial.
Kuller
L H
LH
Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pennsylvania 15261.
D000329:Advertising; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D015897:Comorbidity; D015986:Confounding Factors, Epidemiologic; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D009042:Motivation; D010934:Planning Techniques; D012106:Research / Q000458:organization & administration; D012107:Research Design; D012109:Research Support as Topic / Q000191:economics; D012307:Risk Factors; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use*
D013629:Tamoxifen